1 April 2018 in Advances in Pharmacology and Pharmacy
Background: Diabetes associated with multiple metabolic problems in the body, including bone mineralization remodeling, osteoporosis and increase risk of fracture. Quercetin is natural flavonoids and according to animal studies; it has potent antioxidant, antidiabetic and protective effect against bone loss due to various causes. Objectives: explore effect of quercetin as nutritional supplement administrated orally on some bone mineralization bio-markers such as calcium, vitamin D and osteocalcin in Iraqi diabetic patients. Methods: interventional double-blind placebo randomized controlled study in which 40 patients with type 2 diabetes mellitus (age range 40-45) assigned randomly (using simple randomization) in either control (n=20) or study (n=20) group. Study group received Quercetin oral supplement as 500mg capsule once daily for three months. Venous blood was used for measuring Serum calcium, 25(OH) vitamin D and osteocalcin at base line and after 3 months. Results: After 3 months treatment with Quercetin; levels of Osteocalcin (28.1±7.6), serum calcium (9.2±1.8) and 25(OH) vitamin D (26.6±8.7) were significantly (p<0.05) higher than pretreatment values of osteocalcin (24.0±8.6); serum calcium (7.0±2.2) and 25(OH) vitamin D (20.6±7.7) and control values of serum calcium (6.8±2.0) and 25(OH) vitamin D (20.8±7.4), but not Osteocalcin (25.2±9.0). There was also significant correlation between use of quercetin; elevation of serum calcium and osteocalcin (r= 0.454; p= 0.032), indicating modulation in bone mineralization. Conclusions: Quercetin's use in diabetic patients may elevate Serum level of Calcium; 25(OH) vitamin D and may modulate bone mineralization represented by elevation of osteocalcin.
6 July 2019 in International Journal of Research in Pharmaceutical Sciences
Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but its effect on glucose homeostasis, weight, growth and bone mineralization weren’t well defined. Objectives: the evaluation of oral Taurine effects has used for 3 months on bone mineralization biomarker, glycemic control and body weight in type ll diabetic patients. Methods: the interventional double-blind placebo-controlled study in which 80 patients with type 2 diabetes mellitus (age range 45-55) assigned in either control (n=40), or study group the (n=40) group. The last group has received a 1000mg capsule of Taurine once a day for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1 HbA1C% with fasting blood glucose before and after 3 months. Results: taurine led to significant (p<0.05) rise in osteocalcin, significant lowering in body weight, BMI and there were no significant changes in serum calcium, NTX-1, Vitamin D, HbA1C and fasting blood glucose, all as compared with the control value. Conclusions: the 3 months of oral Taurine are used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%.
30 October 2026 in Folia Medica
Introduction : Acne vulgaris is very common and may have a significant psychosocial effect. Moderate to severe acne is best treated using oral isotretinoin, which has a wide spectrum of adverse drug reactions (ADRs). Aim : To characterize the occurrence, pattern, and severity of isotretinoin-related ADRs in the Iraqi dermatology clinics and clarify clinical and treatment factors linked to its frequency. Patients and methods : This was a prospective observational cohort study carried out at two of the outpatient dermatology clinics in Basra city between January 2024 and December 2025. Patients were recruited consecutively as they were aged 12 years and older and had been taking systemic isotretinoin as the main form of therapy against acne. Results : Out of 420 patients who were screened, 400 patients qualified. The mean age was 21.8 years, and the SD was 4.7 years; 55% of the population was female, and 90% had moderate or severe acne. In general, 360 patients (90%) had at least one ADR, which led to 965 events. The most common were mucocutaneous reactions (88.5% of patients); then there were laboratory abnormalities (22%) and musculoskeletal complaints (around 15%-16%). Biochemical abnormalities were generally mild to moderate, while clinically significant psychiatric events were rare. Moderate/severe ADRs were independently related to female sex, baseline dyslipidemia, and daily dose ≥0.5 mg/kg/day. Conclusion : With the aid of organized monitoring, risk-specific dosing, and strong pregnancy prevention and counseling measures, isotretinoin may be deployed effectively and in a relatively safe way in the Iraqi dermatology clinics.
30 December 2025 in European Journal of Clinical and Experimental Medicine
Introduction and aim. Diabetic kidney disease (DKD), a common complication of type 2 diabetes mellitus, is the leading cause of end-stage renal disease (ESRD). This study aimed to evaluate differences in serum leptin and glucagon-like peptide-1 (GLP-1) levels between diabetic ESRD patients undergoing hemodialysis and healthy controls. Material and methods. A cross-sectional observational study was conducted involving 65 participants: 31 type 2 diabetic patients with ESRD on hemodialysis and 34 healthy controls. Serum leptin and GLP-1 concentrations were measured using enzyme-linked immunosorbent assays. Results. Patients with ESRD exhibited significantly higher serum leptin levels (1.7±1.0 ng/mL) compared to controls (1.4±0.7 ng/mL; p=0.001), and significantly lower GLP-1 levels (19.6±11.2 pmol/L vs. 37.0±25.7 pmol/L; p=0.001). Conclusion. Elevated leptin levels and reduced GLP-1 concentrations in diabetic ESRD patients suggest a potential role of these biomarkers in renal injury and metabolic regulation. The findings highlight the therapeutic promise of GLP-1 receptor agonists in this population.